Data Integrity: History, Issues, and Remediation of Issues

References

1. 1.↵
   US FDA. http://www.fda.gov/ucm/groups/fdagov-public/@fdagov-drugs-gen/documents/document/ucm495891.pdf
2. 2.↵
   MHRA. GMP Data Integrity Definitions and Guidance for Industry March 2015. https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/412735/Data_integrity_definitions_and_guidance_v2.pdf
3. 3.↵
   MHRA. https://mhrainspectorate.blog.gov.uk/2015/06/25/good-manufacturing-practice-gmp-data-integrity-a-new-look-at-an-old-topic-part-1/
4. 4.↵
   MHRA. https://mhrainspectorate.blog.gov.uk/2015/07/14/good-manufacturing-practice-gmp-data-integrity-a-new-look-at-an-old-topic-part-2/
5. 5.↵
   MHRA. https://mhrainspectorate.blog.gov.uk/2015/08/27/good-manufacturing-practice-gmp-data-integrity-a-new-look-at-an-old-topic-part-3/
6. 6.↵
   1. Bargaje C.

   Good Documentation Practice in Clinical Research. Perspect. Clin. Res. 2011, 2 (2), 59–63.

   OpenUrlCrossRefPubMed
7. 7.↵
   Wikipedia. https://en.wikipedia.org/wiki/Data
8. 8.↵
   MHRA. https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/412735/Data_integrity_definitions_and_guidance_v2.pdf
9. 9.↵
   1. McDowall R. D.

   Review and Critique of the MHRA Data Integrity Guidance for Industry—Part 1: Overview. Scientific Computing 2015 (http://scientificcomputing.com)
10. 10.↵
    1. Lopez O.

    2013-2015 Cases of Data Integrity Issues, Rev 31 Jan 2016.
11. 11.↵
    1. Singh A.,
    2. Joshi R.

    Analyzing the State of Data Integrity Compliance in the Indian Pharmaceutical Industry. A survey by Fraud Investigation & Dispute Services, 2015; pp 1–19.
12. 12.↵
    MHRA. Too Much Pressure, March, 2017. https://mhrainspectorate.blog.gov.uk/2017/03/10/too-much-pressure-a-behavioural-approach-to-data-integrity-part-1/
13. 13.↵
    1. Broin B.

    Data Integrity: An Industry Perspective, PDA, Ireland Chapter, Data Integrity, 2015.
14. 14.↵
    1. Perez J.

    Maintaining Data Integrity, Quality Progress 2017, 50 (3), 14.

    OpenUrl
15. 15.↵
    Xavier Health. http://xavierhealth.org/pharmaceutical-industry/pharmalink/videos-presentations
16. 16.
    US FDA. http://www.ecfr.gov/cgi-bin/text-idx?SID=c15722d404a068394a0e8ac954aa9f54&mc=true&node=pt21.4.202&rgn=div5
17. 17.
    US FDA. http://www.fda.gov/ICECI/Inspections/InspectionGuides/ucm074918.htm
18. 18.
    US FDA. http://www.ecfr.gov/cgi-bin/text-idx?SID=c15722d404a068394a0e8ac954aa9f54&mc=true&node=pt21.8.820&rgn=div5
19. 19.
    US FDA. http://www.webpages.uidaho.edu/fish503al/003%20Data%20management%20and%20visualization/003%20Programs%20and%20Data/oecd%20good%20lab%20practices.pdf
20. 20.
    US FDA. http://www.ecfr.gov/cgi-bin/text-idx?SID=c15722d404a068394a0e8ac954aa9f54&mc=true&node=pt21.4.203&rgn=div5
21. 21.
    US FDA. http://www.fda.gov/downloads/ICECI/ComplianceManuals/ComplianceProgramManual/ucm125404.pdf
22. 22.
    US FDA. http://www.fda.gov/downloads/RegulatoryInformation/Guidances/ucm125125.pdf
23. 23.
    US FDA. http://www.fda.gov/Drugs/DevelopmentApprovalProcess/Manufacturing/QuestionsandAnswersonCurrentGoodManufacturingPracticescGMPforDrugs/UCM071836
24. 24.
    EU. http://ec.europa.eu/health/files/eudralex/vol-1/dir_2003_94/dir_2003_94_en.pdf
25. 25.
    US FDA. http://www.fda.gov/Drugs/DevelopmentApprovalProcess/Manufacturing/QuestionsandAnswersonCurrentGoodManufacturingPracticescGMPforDrugs/UCM071836
26. 26.
    ISPE. http://www.ispe.org/gamp-good-practice-guide/electronic-records-signatures
27. 27.
    US FDA. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm073517.pdf
28. 28.
    US FDA. http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?CFRPart=211
29. 29.
    PIC/S. http://www.picscheme.org/pdf/27_pi-011-3-recommendation-on-computerised-systems.pdf
30. 30.
    US FDA. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM070266.pdf
31. 31.
    PIC/S. http://www.picscheme.org/pdf/14_pi-021-3-2-inspection-of-quality-control-laboratories.pdf
32. 32.
    US FDA. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM070273.pdf
33. 33.
    US FDA. http://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/Manufacturing/QuestionsandAnswersonCurrentGoodManufacturingPracticescGMPforDrugs/ucm071871.pdf
34. 34.
    US FDA. http://www.fda.gov/downloads/AboutFDA/CentersOffices/OfficeofGlobalRegulatoryOperationsandPolicy/ORA/UCM136320.pdf
35. 35.
    MHRA. https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/412735/Data_integrity_definitions_and_guidance_v2.pdf
36. 36.
    WHO. http://www.who.int/medicines/areas/quality_safety/quality_assurance/Guidance-on-good-data-management-practices_QAS15-624_16092015.pdf
37. 37.
    US FDA. http://www.fda.gov/downloads/CombinationProducts/UCM336194.pdf
38. 38.
    US FDA. http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?CFRPart=211
39. 39.
    US FDA. http://www.fda.gov/ucm/groups/fdagov-public/@fdagov-drugs-gen/documents/document/ucm495891.pdf
40. 40.
    1. McDowall R. D.

    Review and Critique of the MHRA Data Integrity Guidance for Industry—Part 1: Overview. Scientific Computing 2015 (http://scientificcomputing.com)
41. 41.
    1. Lopez O.

    2013-2015 Cases of Data Integrity Issues, Rev 31 Jan 2016.
42. 42.
    1. Singh A.,
    2. Joshi R.

    Analyzing the State of Data Integrity Compliance in the Indian Pharmaceutical Industry. A survey by Fraud Investigation & Dispute Services, 2015; pp 1–19.
43. 43.
    MHRA. Too Much Pressure, March, 2017. https://mhrainspectorate.blog.gov.uk/2017/03/10/too-much-pressure-a-behavioural-approach-to-data-integrity-part-1/
44. 44.
    1. Broin B.

    Data Integrity: An Industry Perspective, PDA, Ireland Chapter, Data Integrity, 2015.
45. 45.
    1. Perez J.

    Maintaining Data Integrity, Quality Progress 2017, 50 (3), 14.

    OpenUrl
46. 46.
    Xavier Health. http://xavierhealth.org/pharmaceutical-industry/pharmalink/videos-presentations